26667-88-9

Upstream product

• 25804-49-3 tert-butyl 4-hydroxybenzoate 
• 5437-45-6 Benzyl bromoacetate 
• 123-08-0 4-hydroxy-benzaldehyde 
• 613229-85-9 benzyl-2-(4-formylphenoxy)acetate 

Downstream Products

• 613229-96-2 4-Carboxymethoxy-benzoic acid (2R,3R,4S,5R,6S)-3,4,5,6-tetraacetoxy-tetrahydro-pyran-2-ylmethyl ester 
• 613229-89-3 4-Benzyloxycarbonylmethoxy-benzoic acid (2R,3R,4S,5R,6S)-3,4,5-triacetoxy-6-hydroxy-tetrahydro-pyran-2-ylmethyl ester 
• 613229-94-0 4-Carboxymethoxy-benzoic acid (2R,3R,4S,5R,6R)-3,4,5-triacetoxy-6-(4-hydroxy-butoxy)-tetrahydro-pyran-2-ylmethyl ester 
• 613229-87-1 4-Benzyloxycarbonylmethoxy-benzoic acid (2R,3R,4S,5R,6S)-3,4,5,6-tetraacetoxy-tetrahydro-pyran-2-ylmethyl ester 
• 613229-98-4 4-(4-Hydroxy-butoxycarbonylmethoxy)-benzoic acid (2R,3R,4S,5R,6S)-3,4,5,6-tetraacetoxy-tetrahydro-pyran-2-ylmethyl ester 
• 613229-90-6 4-Benzyloxycarbonylmethoxy-benzoic acid (2R,3R,4S,5R,6R)-3,4,5-triacetoxy-6-(2,2,2-trichloro-acetimidoyloxy)-tetrahydro-pyran-2-ylmethyl ester 
• 613229-92-8 4-Benzyloxycarbonylmethoxy-benzoic acid (2R,3R,4S,5R,6R)-3,4,5-triacetoxy-6-(4-benzyloxy-butoxy)-tetrahydro-pyran-2-ylmethyl ester 

Relevant academic research and scientific papers

(S)-3-(Carboxyformamido)-2-(3-(carboxymethyl)ureido)propanoic Acid as a Novel PSMA Targeting Scaffold for Prostate Cancer Imaging

In an effort to seek novel agents targeting prostate-specific membrane antigen (PSMA), 16 ligands (L1-L16) with structural modifications in S1′ binding pocket were synthesized and evaluated for PSMA inhibition. (S)-3-(Carboxyformamido)-2-(3-(carboxymethyl)ureido)propanoic acids proved to be potent PSMA ligands with Ki values ranging from 0.08 nM to 8.98 nM, which are in the range of or are higher in potency compared to previously published urea-based ligands. Computational docking was performed to study the binding mode of the two most potent ligands discovered. FITC-conjugated L14 could selectively stain PSMA+ LNCaP cells over PSMA- PC3 cells. IRDye800CW conjugated L16 can effectively image tumors in a murine xenograft model of prostate cancer.

Prostate-specific membrane antigen targeting inhibitor, application and probe

The invention belongs to the field of nuclear medicine, and relates to a prostate specific membrane antigen targeting inhibitor, application and a probe. The inhibitor is at least one of compounds with a structure shown as a formula I. The uptake of the PSMA targeting probe provided by the invention in tumors is 1.45 times that of GaPSMA617 (one of the existing gold standards), and the ratiosof tumor/muscle and tumor/kidney are equivalent to those of GaPSMA617. Therefore, the probe is a dencichine PSMA targeted molecular probe with a very good application prospect.

Synthesis of 1,6-ansaglycosides

Two representatives of the 1,6-ansaglycoside class of compounds have been synthesized by different ring-closing strategies.